The serum levels of IL-18 were significantly higher in the COVID-19 patients with MAS compared with COVID-19 patients without MAS (28) and were associated with disease severity and poor clinical outcome in COVID-19 patients (29, 30). This evidence concerns the gene IL18 and COVID-19.